Auvergne-Rhône-Alpes Network for Drug Discovery in Oncology

Cibles et outils pour l’imagerie moléculaire et la thérapie (TaToo)

Equipe de recherche
RESPONSABLE CO-RESPONSABLE
Françoise DEGOUL
francoise.degoul@inserm.fr
33(0)473150814  
Valérie WEBER
valerie.weber@uca.fr
33(0)473150821  

CHAMPS D’EXPERTISE

Organic synthesis, radiolabelling

ACTIVITES DE RECHERCHE / SERVICES

The objectives of UMR 1240 INSERM/IMOST are the development of tools for theranostic strategies, in particular radiopharmaceuticals, with researches mainly dedicated to oncology.

Based on a two teams structure entitled respectively “Targets and tools for imaging and therapy” and “Translational research in functional imaging, radiopharmaceuticals and theranostic biomarkers”, IMOST brings together specialists of complementary disciplines, (chemists, radiochemists, pharmacologists, molecular biologists, researchers in preclinical imaging, physicians), (as well as high technology platforms), which creates a scientific environment for drug development and rapid translation from bench to bed,

Researches are focused, on targeting strategies through the use of target-specific ligands conjugated to agents being radiolabeled for both diagnostic imaging and targeted radionuclide therapy (TRT), as well as drugs (hypoxia activated prodrugs) and nano-objects. Among the main three researches axis conducted by TaToo team, one deals with melanin/proteoglycan ligands, and on new vectors/targets for cancer. The second theme consists in  targeting specific proteins involved in dissemination and metabolic reprogramming using radiolabeled antibodies and small ligands.

The last part develops methodological approaches for radiolabeling for imaging and radionuclide therapy, pretargeting radioimmunotherapy with click chemistry and functionalization of nano-objects.

COMPETENCES / MOYENS TECHNIQUES

IMoST  is equipped with tools for organic synthesis and analytical controls, fully-automated radiolabelling for high energy radionuclides (e.g., 18F,124I, 64Cu, 131I, 177Lu), hot cells used for the handling of medium energy isotopes (e.g. 99mTc, 111In, 125I,..) radionuclides.

For demonstrating  the  proof of concept, IMoST has cellular and post genomic equipments, as well as ex vivo and in vivo imaging facilities (spect-ct, PET, CT, whole body autoradiography for small animals, optical imaging), authorized housing for small animals and rabbit including shielded cages for animals injected with radiopharmaceuticals.

OU NOUS TROUVER ?

UMR1240 Inserm, UCA Imagerie Moléculaire et Stratégies Théranostiques (IMoST)
58 rue Montalembert
63005 Clermont-Ferrand